C4 Therapeutics, Inc. Stock Split Ratio
C4 Therapeutics, Inc. (CCCC) reported Stock Split Ratio of 11.86% for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2022-02-24
- C4 Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2021-03-31 was 11.86%.
- C4 Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2021 was 11.86%, a 0.00% change from fiscal 2020.
- C4 Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2020 was 11.86%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | 11.86% 10-K · filed 2022-02-24 | ||||
| 2021-09-30 | 11.86% 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | 11.86% 10-Q · filed 2021-08-11 | ||||
| 2021-03-31 | 11.86% 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | 11.86% 10-K · filed 2021-03-11 | ||||
| 2020-10-06 | 11.86% 10-K · filed 2021-03-11 | ||||
| 2020-09-25 | 11.86% 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |